The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.
Dr Reinhardt’s background, qualifications and experience fit perfectly with the goalsand expectations of immatics as the company looks to the rapid and further successful development of it’s lead clinical projects in renal cell carcinoma and colorectal cancer. Dr Reinhardt joins immatics from Micromet, Inc., where he has headed the clinicaldevelopment team for the past four years, initially as Senior Vice President, ClinicalDevelopment, and as Chief Medical Officer since June 2007. In this role, he wasresponsible for all corporate medical, clinical, and regulatory activities. During histenure he headed the development team and moved various compounds into the clinic and successfully completed two key phase II studies. Dr. Reinhardt was alsosignificantly involved in achieving Micromet’s public listing on NASDAQ through areverse merger in 2006 and in repeated major financing rounds.Before joining Micromet in 2005, Dr Reinhardt worked as International Medical Leader for Herceptin® at Hoffmann-La Roche (Basel, Switzerland) and before that as Head of Clinical Development at Fresenius Biotech (Munich, Germany), where he successfully developed later stage niche indication strategies leading to the recent approval of Removab®.Prior to joining industry, Dr Reinhardt held medical positions and worked at variousacademic institutions (University of Tuebingen, Max Planck Institute, Munich) tocomplete his curriculum in Neurology. Between 1991 and 1995, Dr Reinhardtcompleted his Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany, and received a Medical Degree in 1994 from the University ofMunich, Germany. He is a Visiting Professor for Pharmaceutical Medicine at theUniversity of Basel.“We are delighted to have been able to attract a CMO of Carsten‘s caliber andexperience”, commented Paul Higham, CEO of immatics. “He has successfully moved immunotherapy products into late stage clinical development. This combined with Carsten’s experience of working within a successful biotech company and his in-depth knowledge of immunotherapy matched exactly the profile we were looking for, as we enter late stage clinical development.”“I am very pleased to be joining immatics at this exciting stage of the company’sdevelopment” said Dr Reinhardt. “The encouraging results seen so far with the projects in clinical development and the high potential discovery platform both offer much promise in reaching the goals of immunotherapy in cancer treatment. I am looking forward to working with the team at immatics to realize this huge potential through successful late-stage clinical development of the lead projects.”
Immatics biotechnologies is an independent biopharmaceutical company dedicated tothe development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specificallystimulate the immune system against cancer cells. Its lead products – IMA901 for thetherapy of renal cell cancer and IMA910 for the treatment of colon cancer – are currently investigated in international phase II clinical studies. Since its foundation in2000, immatics has raised more than €54 million (US$ 72million) in private equity intwo financing rounds. The company has a headcount of more than 65 people and isbased in Tuebingen and Munich, Germany.
Katrin Eckert, Assistant to the Managementimmatics biotechnologies GmbHPhone: +49-7071-5397-110E-mail: media(at)immatics.com